International Biotech Firm Funds Research Into Aging Through Foundation of UMDNJ
NEW BRUNSWICK, N.J., March 16, 2011 /PRNewswire-USNewswire/ -- Working with the Foundation of UMDNJ and New Jersey Health Foundation, Rostock Biotech Research Ltd, headquartered in Moscow, Russia, has donated $100,000 to fund the research of Dr. Alexey G. Ryazanov, a professor in the Department of Pharmacology at UMDNJ-Robert Wood Johnson Medical School (RWJMS) and a member of The Cancer Institute of New Jersey.
The Blue Sky Research and Development Fund in Pharmacology in the Department of Pharmacology allows Dr. Ryazanov to investigate cellular and molecular mechanisms of aging and age-related diseases and to pursue research that would lead to better understanding of the fundamental principles of drug action.
"This funding permits Dr. Ryazanov to pursue cutting edge research without limitations on ideas or hypothesis," explained Dmitri Khan of Rostock Group, parent of Rostock Biotech Research. "We hope it will open the door for Dr. Ryazanov and his team to make unlimited discoveries that will have a positive impact in the future."
Working in concert with donors, the Foundation of UMDNJ/New Jersey Health Foundation can develop fund agreements that are individually tailored to meet donor needs.
"Because many of our donors wish to remain connected to the areas they help fund, this agreement, like many others we have developed, provides an opportunity for representatives from Rostock to meet with department representatives periodically to discuss innovative findings that might come about as a result of this research," explained George F. Heinrich, M.D., vice chair and CEO of the Foundation. "It's very exciting for a researcher to be able to share his or her results with others who are passionate about their work."
To learn more about how you can fund research in an area that
means the most to you, contact James M. Golubieski, Foundation
president, at (908) 731-6601 or